251 related articles for article (PubMed ID: 17899549)
1. Programmed cell death 1 (PD-1) and its ligand PD-L1 are required for allograft tolerance.
Wang L; Han R; Hancock WW
Eur J Immunol; 2007 Oct; 37(10):2983-90. PubMed ID: 17899549
[TBL] [Abstract][Full Text] [Related]
2. Involvement of the programmed death-1/programmed death-1 ligand pathway in CD4+CD25+ regulatory T-cell activity to suppress alloimmune responses.
Kitazawa Y; Fujino M; Wang Q; Kimura H; Azuma M; Kubo M; Abe R; Li XK
Transplantation; 2007 Mar; 83(6):774-82. PubMed ID: 17414712
[TBL] [Abstract][Full Text] [Related]
3. Dual control of antitumor CD8 T cells through the programmed death-1/programmed death-ligand 1 pathway and immunosuppressive CD4 T cells: regulation and counterregulation.
Currie AJ; Prosser A; McDonnell A; Cleaver AL; Robinson BW; Freeman GJ; van der Most RG
J Immunol; 2009 Dec; 183(12):7898-908. PubMed ID: 20007574
[TBL] [Abstract][Full Text] [Related]
4. Stimulating PD-1-negative signals concurrent with blocking CD154 co-stimulation induces long-term islet allograft survival.
Gao W; Demirci G; Strom TB; Li XC
Transplantation; 2003 Sep; 76(6):994-9. PubMed ID: 14508368
[TBL] [Abstract][Full Text] [Related]
5. Blockade of the interaction between PD-1 and PD-L1 accelerates graft arterial disease in cardiac allografts.
Koga N; Suzuki J; Kosuge H; Haraguchi G; Onai Y; Futamatsu H; Maejima Y; Gotoh R; Saiki H; Tsushima F; Azuma M; Isobe M
Arterioscler Thromb Vasc Biol; 2004 Nov; 24(11):2057-62. PubMed ID: 15374847
[TBL] [Abstract][Full Text] [Related]
6. Antibody-mediated signaling through PD-1 costimulates T cells and enhances CD28-dependent proliferation.
del Rio ML; Penuelas-Rivas G; Dominguez-Perles R; Ramirez P; Parrilla P; Rodriguez-Barbosa JI
Eur J Immunol; 2005 Dec; 35(12):3545-60. PubMed ID: 16285013
[TBL] [Abstract][Full Text] [Related]
7. The programmed death 1/programmed death ligand 1 inhibitory pathway is up-regulated in rheumatoid synovium and regulates peripheral T cell responses in human and murine arthritis.
Raptopoulou AP; Bertsias G; Makrygiannakis D; Verginis P; Kritikos I; Tzardi M; Klareskog L; Catrina AI; Sidiropoulos P; Boumpas DT
Arthritis Rheum; 2010 Jul; 62(7):1870-80. PubMed ID: 20506224
[TBL] [Abstract][Full Text] [Related]
8. Transplantation of NIT-1 cells expressing pD-L1 for treatment of streptozotocin-induced diabetes.
Wen X; Zhu H; Li L; Li Y; Wang M; Liu J; Yang D; Liao W; Shen G
Transplantation; 2008 Dec; 86(11):1596-602. PubMed ID: 19077895
[TBL] [Abstract][Full Text] [Related]
9. T-cell suppression by programmed cell death 1 ligand 1 on retinal pigment epithelium during inflammatory conditions.
Sugita S; Usui Y; Horie S; Futagami Y; Aburatani H; Okazaki T; Honjo T; Takeuchi M; Mochizuki M
Invest Ophthalmol Vis Sci; 2009 Jun; 50(6):2862-70. PubMed ID: 19182257
[TBL] [Abstract][Full Text] [Related]
10. Role of the programmed Death-1 pathway in the suppressive activity of alternatively activated macrophages in experimental cysticercosis.
Terrazas LI; Montero D; Terrazas CA; Reyes JL; RodrÃguez-Sosa M
Int J Parasitol; 2005 Nov; 35(13):1349-58. PubMed ID: 16126211
[TBL] [Abstract][Full Text] [Related]
11. Suppression of bystander T helper 1 cells by iris pigment epithelium-inducing regulatory T cells via negative costimulatory signals.
Sugita S; Horie S; Yamada Y; Keino H; Usui Y; Takeuchi M; Mochizuki M
Invest Ophthalmol Vis Sci; 2010 May; 51(5):2529-36. PubMed ID: 19959639
[TBL] [Abstract][Full Text] [Related]
12. Blockade of programmed death-1 in young (New Zealand black x New Zealand white)F1 mice promotes the activity of suppressive CD8+ T cells that protect from lupus-like disease.
Wong M; La Cava A; Singh RP; Hahn BH
J Immunol; 2010 Dec; 185(11):6563-71. PubMed ID: 21041733
[TBL] [Abstract][Full Text] [Related]
13. Differential effects of costimulatory pathway modulation on corneal allograft survival.
Watson MP; George AJ; Larkin DF
Invest Ophthalmol Vis Sci; 2006 Aug; 47(8):3417-22. PubMed ID: 16877411
[TBL] [Abstract][Full Text] [Related]
14. Programmed death-1-programmed death-L1 interaction is essential for induction of regulatory cells by intratracheal delivery of alloantigen.
Aramaki O; Shirasugi N; Takayama T; Shimazu M; Kitajima M; Ikeda Y; Azuma M; Okumura K; Yagita H; Niimi M
Transplantation; 2004 Jan; 77(1):6-12. PubMed ID: 14724428
[TBL] [Abstract][Full Text] [Related]
15. Overexpression of program death-1 in T cells has mild impact on allograft survival.
Chen L; Hussien Y; Hwang KW; Wang Y; Zhou P; Alegre ML
Transpl Int; 2008 Jan; 21(1):21-9. PubMed ID: 18076633
[TBL] [Abstract][Full Text] [Related]
16. PD-L1/PD-1 signal deficiency promotes allogeneic immune responses and accelerates heart allograft rejection.
Wang W; Carper K; Malone F; Latchman Y; Perkins J; Fu Y; Reyes J; Li W
Transplantation; 2008 Sep; 86(6):836-44. PubMed ID: 18813109
[TBL] [Abstract][Full Text] [Related]
17. Keratinocyte-associated B7-H1 directly regulates cutaneous effector CD8+ T cell responses.
Ritprajak P; Hashiguchi M; Tsushima F; Chalermsarp N; Azuma M
J Immunol; 2010 May; 184(9):4918-25. PubMed ID: 20363965
[TBL] [Abstract][Full Text] [Related]
18. CD4+PD-1+ T cells acting as regulatory cells during the induction of anterior chamber-associated immune deviation.
Meng Q; Yang P; Li B; Zhou H; Huang X; Zhu L; Ren Y; Kijlstra A
Invest Ophthalmol Vis Sci; 2006 Oct; 47(10):4444-52. PubMed ID: 17003438
[TBL] [Abstract][Full Text] [Related]
19. Gene transfer of programmed death ligand-1.Ig prolongs cardiac allograft survival.
Dudler J; Li J; Pagnotta M; Pascual M; von Segesser LK; Vassalli G
Transplantation; 2006 Dec; 82(12):1733-7. PubMed ID: 17198268
[TBL] [Abstract][Full Text] [Related]
20. PD-L2 is a second ligand for PD-1 and inhibits T cell activation.
Latchman Y; Wood CR; Chernova T; Chaudhary D; Borde M; Chernova I; Iwai Y; Long AJ; Brown JA; Nunes R; Greenfield EA; Bourque K; Boussiotis VA; Carter LL; Carreno BM; Malenkovich N; Nishimura H; Okazaki T; Honjo T; Sharpe AH; Freeman GJ
Nat Immunol; 2001 Mar; 2(3):261-8. PubMed ID: 11224527
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
